Patient-provided, patient-focused data from the Patient Registry has been a core component of the LRG’s research model. Out of the foundation of real world data, we conducted a Side Effects Survey in the early [...]
Although targeted medicine has brought about immense progress in cancer treatment, there are still enormous challenges regarding patient survival. Randomized clinical trials (RCTs) driven by lab-based research have been the gold standard for identifying new [...]
On April 6th, 2018, Executive Director, Norman Scherzer; Data Analyst, Jerry Call; Real World Evidence Scientist, Yu Wang, and Patient Registry Director, Denisse Montoya, of The Life Raft Group, were invited to present at [...]
Executive Director, Norman Scherzer, and Real World Evidence Data Scientist, Dr. Yu Wang, of the Life Raft Group recently attended the ASCO (American Society of Clinical Oncologists) 2018 meeting in Chicago. Dr. Wang describes [...]
Senior Director of Program Operations, Sara Rothschild, recently represented the Life Raft Group at the SPAEN (Sarcoma Patients EuroNet) meeting. Subsequent to the meeting, over 300 medical professionals gathered for the 7th annual ESMO [...]
Dr. Jason Sicklick and Norman Scherzer co-present poster at 2017 CTOS meeting. Norman Scherzer, Executive Director of The Life Raft Group, recently co-presented a poster at the 2017 CTOS (Connective Tissue Oncology [...]
The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor (GIST) has awarded its science prize for the eighth time. The 2017 GIST prize, worth CHF 10,000, was awarded to Dr. [...]
The following is a recap of the presentations and posters from the CTOS conference held in Hawaii, with commentary by David Josephy. Dr. Michael Heinrich, David Josephy and Norman Scherzer CTOS 2017 Presentations [...]
The latest edition of the GIST and Sarcoma Journal is now available online. The GIST and Sarcoma Journal is a comprehensive and authoritative resource for scientifically valid information for physicians, allied healthcare professionals [...]
A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]
